Funded Grants

Dr. Belzil began her research career as a PhD student at the Université de Montréal under the guidance of world renowned geneticist and Director of the Montreal Neurological Institute and Hospital, Dr. Guy Rouleau.

Primary progressive aphasia (PPA) is a form of dementia which impairs the ability to understand spoken and written language but other cognitive skills (including memory) remain intact for several years after its onset.

People with dementia are at a high risk for falls which are a leading cause of injury and can contribute to loss of independence and quality of life.

For this project, Dr. Park will examine how abnormalities in RNA binding proteins (RBPs) – in particular, one called Matrin 3 (MATR3) – can lead to ALS. MATR3 was discovered to be a genetic cause of ALS in 2014 and has yet to be studied in any detail.

One of the largest predictors of mental illness is childhood emotional and behavioural problems (EBP, e.g., aggression, anxiety, depression), which occur in 12-26% of children under age 6 years.

For this project Dr. Sanjay Kalra and his team aims to improve on current techniques to use magnetic resonance imaging (MRI) as a readily available way to examine if a potential new treatment is working to slow down progression of ALS.

The McConnell Brain Imaging Centre (BIC) is a major platform and research centre entirely dedicated to brain imaging. It features 7 multimodal imaging core units (MRI, PET, MEG, EEG for humans and disease models), comprehensive high-performance computing and data storage resources, and prominent expertise in biomedical image and signal analysis.

Moving neuroscience research from the lab and turning it into a product is extremely challenging. Even the most groundbreaking technologies may never improve a patient’s life if the commercialization path is not successfully navigated.

Stroke is a leading cause of adult and childhood focal brain injury and disability.

Decades of dance research have demonstrated the positive benefits of dance in terms of improving quality of life and reducing symptomatology for diverse groups of participants.